Photo from archive.org
In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence… Click to show full abstract
In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 inhibition in COVID-19 development and progression.
Keywords:
dpp4 inhibitors;
diabetes prevalence;
among covid;
covid deaths;
correlate diabetes;
prevalence among
Journal Title: Diabetes Research and Clinical Practice
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes Research and Clinical Practice
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!